T1	Participants 40 80	patients with fibrocystic breast disease
T2	Participants 156 192	patients with fibrocystic mastopathy
T3	Participants 215 356	Patients with diagnosis of fibrocystic breast disease were included in a prospective longitudinal blind double, controlled with placebo study
T4	Participants 1665 1692	fribrocystic breast disease
